Merck KGaA (FRA: MRK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 65.00B |
| Revenue (ttm) | 20.96B |
| Net Income (ttm) | 2.70B |
| Shares Out | n/a |
| EPS (ttm) | 6.19 |
| PE Ratio | 24.11 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Apr 29, 2024 |
| Volume | 33 |
| Average Volume | 788 |
| Open | 144.00 |
| Previous Close | 145.00 |
| Day's Range | 144.00 - 145.55 |
| 52-Week Range | 136.65 - 176.50 |
| Beta | n/a |
| RSI | 55.50 |
| Earnings Date | Mar 6, 2025 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]
Financial Performance
In 2023, Merck KGaA's revenue was 20.99 billion, a decrease of -5.57% compared to the previous year's 22.23 billion. Earnings were 2.82 billion, a decrease of -15.09%.
Financial StatementsNews
Merck KGaA says high asset prices call for prudent M&A approach
The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.
MilliporeSigma Partners with Opentrons Labworks, Inc., Supporting Lab of the Future
Custom robotic workstation automates company’s broad portfolio of biology assays for academia, biotech, and pharma Meets growing need for autonomous tools that boost throughput and reproducibility Pro...
Merck KGaA, Darmstadt, Germany Announces Launch of Caregiver Leave Benefit, Strengthening Inclusive Family-Friendly Offerings
Caregiver Leave Benefit to offer financially protected 10-day minimum leave to employees globally Primarily aimed to support the care of critically and terminally ill immediate family members Program ...
EU ship can be 'turned around,' Merck KGaA CEO says
Beln Garijo, CEO of Merck KGaA, weighs in on Europe's competitiveness and the pharma giant's preparations for the impact of potential U.S. trade tariffs.
Mirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer
TAMPA, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient is living, non-genetically al...
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell culture portfolio of media, reagen...
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
HUB internationally recognized pioneer in organoid development Acquisition expands MilliporeSigma’s 2D and 3D cell culture portfolio Organoids part of fastest growing cell culture segment; hold potent...
Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor RelationsBelen...
Merck KGaA 2024 Q3 - Results - Earnings Call Presentation
Merck KGaA continues focus on strengthening pipeline with external innovation, says CFO on drug trials
Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.
Merck KGaA Non-GAAP EPS of €2.30, revenue of €5.27B; updates FY24 outlook
Merck KGaA Q3 earnings rise faster than expected on lower costs
Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by cost-cutting measures and temporarily lower spending on drug research and development.
Merck KGaA Specifies Guidance Amid Soft Semiconductor Market
Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic slump alongside positive growth trends in its other two businesses.
Merck KGaA, Darmstadt, Germany and Intel Launch Academic Research Program in Europe for More Sustainable Semiconductor Manufacturing
Following the announcement of the multidisciplinary research program last year, the selection process for funded projects has been completed Six projects involving eleven scientific institutions from ...
Merck KGaA: A Continued Long-Term Upside Despite Some Lag
Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 was mixed-positive. Read more here.
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Shares of Charter Communications, Inc. (NASDAQ: CHTR) rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter EPS and revenues. Charter Communications...
AI is driving semiconductor industry, says CEO Electronics at Merck KgaA
Kai Beckmann, a member of the executive board and the CEO Electronics at Merck KgaA, discusses the use of AI in the semiconductor industry.
Merck KGaA Shares Jump on Expectations of AI Boost
The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously expected over the medium term.
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT064635...
Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO Helene...
Merck KGaA: The Drop Makes The Upside All The Sweeter
Merck KGaA remains undervalued with strong fundamentals and diverse business portfolio in healthcare, life sciences, and electronics. The company has above-average margins compared to the broader mark...
Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating ...
Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new research from the company's diverse oncology portfolio will be presented at the 2024 American ...
Merck KGaA (MKGAF) Q1 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q1 2024 Results Conference Call May 15, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Ma...
Merck KGaA's Q1 adjusted profit declines less than feared
Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.